Shan Riku Sakakibara Sells 8,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $98.22, for a total value of $785,760.00. Following the sale, the insider owned 212,000 shares of the company’s stock, valued at approximately $20,822,640. This represents a 3.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $99.30 on Friday. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $4.57 billion and a PE ratio of 180.55. The firm’s 50 day moving average price is $87.67 and its 200-day moving average price is $88.10. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. During the same quarter last year, the firm posted ($0.39) earnings per share. The business’s quarterly revenue was up 83.8% compared to the same quarter last year. Equities research analysts expect that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Trading of Billiontoone

Several institutional investors have recently made changes to their positions in the business. Green Alpha Advisors LLC bought a new stake in Billiontoone during the 4th quarter valued at approximately $436,000. FNY Investment Advisers LLC purchased a new stake in Billiontoone during the 4th quarter valued at approximately $497,000. Massachusetts Financial Services Co. MA purchased a new stake in Billiontoone during the 4th quarter valued at approximately $13,373,000. Baillie Gifford & Co. bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Billiontoone in the fourth quarter worth $1,348,000.

Wall Street Analysts Forecast Growth

BLLN has been the subject of several analyst reports. Wells Fargo & Company reduced their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. BTIG Research cut their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. JPMorgan Chase & Co. upped their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Guggenheim boosted their price objective on Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.